TrendHuman CD38: a glycoprotein in search of a function
References (21)
- et al.
Hum. Immunol.
(1984) - et al.
Biochem. Biophys. Res. Commun.
(1993) - et al.
Trends Biochem. Sci.
(1992) - et al.
J. Biol. Chem.
(1989) - et al.
Biochem. Biophys. Res. Commun.
(1993) - et al.
Biochem. Biophys. Res. Commun.
(1993) - et al.
J. Biol. Chem.
(1993) - et al.
- et al.
- et al.
Cell
(1981)
There are more references available in the full text version of this article.
Cited by (340)
Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture
2022, Transplant ImmunologyImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality
2022, Drug Discovery TodayCitation Excerpt :Muylle et al. showed that, without a preload of unlabeled rituximab, an optimized 89Zr-rituximab immunoPET/CT scanning strategy enabled higher tumor uptake and clearer tumor visualization.25 CD38 is a transmembrane glycoprotein that is expressed on nearly all myeloma cells, as well as at lower levels on normal lymphoid cells and myeloid cells.26 Several mAbs (e.g., daratumumab) targeting CD38 have been investigated for imaging CD38-positive cancers.
Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells
2021, Critical Reviews in Oncology/Hematology
Copyright © 1994 Published by Elsevier Ltd.